Jun Takahashi

Overview of IPS cell prospects for clinical impact

IPS-cell-clincial-trials-map

IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for …

Overview of IPS cell prospects for clinical impact Read More »

3X recent stem cell & regenerative medicine good news

Stem cells spina bifida

In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples. Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf natural killer-based cancer immunotherapy. I expect …

3X recent stem cell & regenerative medicine good news Read More »

Good final grades on my 20 x 2018 stem cell predictions

stem-cell-crystal-ball-300x3001

Each year I make a list of stem cell predictions for the following year and I’ll release my predictions for 2019 soon, but first I’m grading how my 20 predictions for 2018 turned out. It seems I did better than usual predicting what would happen this year. I only got a couple partial credit or …

Good final grades on my 20 x 2018 stem cell predictions Read More »

Hope on Parkinson’s front: Japan IPSC trial 1st patient

Fig-3i-Kikuchi-et-al.-Nature-2017-IPS-cell-Parkinsons-

In Parkinson’s Disease patients develop neurological dysfunction as they lose a special kind of brain cell called dopaminergic (or dopamine) neurons. While a number of different approaches to this disease have been studied for decades, nothing has proven particularly successful in slowing its progression. As a result there has been a big need for novel thinking …

Hope on Parkinson’s front: Japan IPSC trial 1st patient Read More »

Launch of Jun Takahashi IPS Cell Trial For Parkinson’s Disease

Jun-Takahashi-252x3001

A much-anticipated induced pluripotent stem (IPS) cell trial for Parkinson’s Disease reportedly will soon launch led by Professor Jun Takahashi. The news broke on Yahoo Japan, which included an unusual number of appropriately sober statements regarding the trial, even though it is an exciting trial as well, compared to most media stories on stem cells. …

Launch of Jun Takahashi IPS Cell Trial For Parkinson’s Disease Read More »

Ian Wilmut, who cloned Dolly, opens up about his Parkinson’s Disease

Ian-Wilmut

One of the most famous living biological scientists, Sir Ian Wilmut, just announced that he has Parkinson’s Disease. I wish him the best in dealing with this illness. Wilmut is very well-known for having cloned the first mammal, Dolly the Sheep. This work followed on the earlier breakthrough by Sir John Gurdon of cloning the …

Ian Wilmut, who cloned Dolly, opens up about his Parkinson’s Disease Read More »

On the threshold of cell therapy for Parkinson’s disease

Dopamine-neurons-derived-from-a-Parkinsons-disease-patients-iPSCs-Tyrosine-hydroxylase-1

By Jeanne Loring There are ten million people in the world who have Parkinson’s disease. 125,000 of these are living in California.  People with the disease often have to step away from their jobs because the main symptoms – tremor or freezing up of muscles – make it difficult to get through a whole day …

On the threshold of cell therapy for Parkinson’s disease Read More »

Good stem cell news as Takahashi IPS Cell Trial to Resume

Masayo-Takahashi

Some good news today as the pioneering induced pluripotent stem (IPS) cell trial led by Dr. Masayo Takahashi will resume. This clinical study with a focus on macular degeneration has been on hold for quite some time due to regulatory changes in Japan. There had also been concerns over mutations in the 2nd patient’s IPS …

Good stem cell news as Takahashi IPS Cell Trial to Resume Read More »

Parkinson’s IPS cell trial in Japan switching to allogeneic

Jun-Takahashi

What’s better for stem cell trials such as for vision loss or Parkinson’s Disease: allogeneic or autologous cells? In a major shift earlier this year, the induced pluripotent stem (IPS) cell trial in Japan for treatment of macular degeneration (MD) switched gears from using the patients’ own cells (called “autologous”) to using banked cells from …

Parkinson’s IPS cell trial in Japan switching to allogeneic Read More »

Michael Cea ISSCR chat with Jeanne Loring on stem cell field

Lewy_Body_alphaSynuclein

By Michael Cea Jeanne Loring of the Scripps Research Institute in La Jolla, California kindly sat down with me at the ISSCR annual meeting for a broad discussion of her history, views on the field and developments in the science. I found Jeanne a refreshing character, as I did a number of others I was fortunate to …

Michael Cea ISSCR chat with Jeanne Loring on stem cell field Read More »